Last reviewed · How we verify

NCT02930902

Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery

Completed Phase 1 Last updated 9 February 2023
What this trial tests

Phase 1 trial testing Gemcitabine Hydrochloride in Resectable Pancreatic Carcinoma in 9 participants. Completed in 3 January 2023.

Timeline
20 February 2017
Primary endpoint
3 January 2023
3 January 2023

Quick facts

Lead sponsorM.D. Anderson Cancer Center
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment9
Start date20 February 2017
Primary completion3 January 2023
Estimated completion3 January 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Resectable Pancreatic Carcinoma or Stage I Pancreatic Cancer AJCC v6 and v7. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase Ib trial studies the side effects and best way to give pembrolizumab and paricalcitol with or without chemotherapy in patients with pancreatic cancer that can be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may find tumor cells and help carry tumor-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and paricalcitol with or without chemotherapy before surgery may help to control the disease.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Challenges and Opportunities for Pancreatic Cancer Immunotherapy.
    Bear AS, Vonderheide RH, O'Hara MH. · · 2020 · cited 500× · PMID 32946773 · DOI 10.1016/j.ccell.2020.08.004
  2. Tumor microenvironment participates in metastasis of pancreatic cancer.
    Ren B, Cui M, Yang G, Wang H, et al · · 2018 · cited 442× · PMID 30060755 · DOI 10.1186/s12943-018-0858-1
  3. The Extracellular Matrix and Pancreatic Cancer: A Complex Relationship.
    Weniger M, Honselmann KC, Liss AS. · · 2018 · cited 208× · PMID 30200666 · DOI 10.3390/cancers10090316
  4. Current and future immunotherapeutic approaches in pancreatic cancer treatment.
    Farhangnia P, Khorramdelazad H, Nickho H, Delbandi AA. · · 2024 · cited 153× · PMID 38835055 · DOI 10.1186/s13045-024-01561-6
  5. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
    Kabacaoglu D, Ciecielski KJ, Ruess DA, Algül H. · · 2018 · cited 152× · PMID 30158932 · DOI 10.3389/fimmu.2018.01878
  6. The PDAC Extracellular Matrix: A Review of the ECM Protein Composition, Tumor Cell Interaction, and Therapeutic Strategies.
    Perez VM, Kearney JF, Yeh JJ. · · 2021 · cited 103× · PMID 34692532 · DOI 10.3389/fonc.2021.751311
  7. The Extracellular Matrix in Pancreatic Cancer: Description of a Complex Network and Promising Therapeutic Options.
    Ferrara B, Pignatelli C, Cossutta M, Citro A, et al · · 2021 · cited 94× · PMID 34503252 · DOI 10.3390/cancers13174442
  8. The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment.
    Lafaro KJ, Melstrom LG. · · 2019 · cited 67× · PMID 30558722 · DOI 10.1016/j.ajpath.2018.09.009

Verify or expand the search:

Other trials of Gemcitabine Hydrochloride

Trials testing the same drug.

Other recruiting trials for Resectable Pancreatic Carcinoma

Currently open trials in the same condition.

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02930902.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing